Orchard Therapeutics Plc (ORTX) - News Archive

Showing 9 of 9 results.

Orchard Therapeutics: Unleashing the Game-changer - HSC Gene Therapy's Versatility in Tackling Neurometabolic Diseases at ASGCT 2024.

These presentations underpinned the tremendous scope and variety of HSC gene therapy a pioneering and innovative treatment that is shaking the foundations of our perspective on the management of challenging medical cond...

May 7, 2024 Product Service News

Orchard Therapeutics' CEO Dr. Bobby Gaspar: A Global Pioneer in Health Innovation Named in the 2024 TIME100 Health List.

In a testament to his monumental impact and revolutionary advancements in the global health sector, Dr. Bobby Gaspar, co-founder and Chief Executive Officer (CEO) of Orchard Therapeutics, has been named to the inaugural...

May 3, 2024 Announcement

Revolutionary Gene Therapy for Early-onset Metachromatic Leukodystrophy Launches in the U.S., Offering Hope and Convenience for Affected Families

Orchard Therapeutics, a global gene therapy company, recently announced its plans for the U.S. launch of Lenmeldy (atidarsagene autotemcel), the first and only approved therapy for children with Early-onset Metachromati...

Mar 20, 2024 Clinical Study

Orchard Therapeutics: Pioneering Breakthrough Treatment while Navigating Financial Waters

Orchard Therapeutics: Breakthrough Treatment for Metachromatic Leukodystrophy and Financial ChallengesIn a groundbreaking development, Orchard Therapeutics has received FDA approval for its therapy, Lenmeldy (atidarsage...

Mar 18, 2024 Management Announcement

Orchard Therapeutics Embarks on Ground-breaking Gene Therapy Trial for MPS-I Hurler Syndrome with OTL-203 Trial Launch

Orchard Therapeutics, a leading global gene therapy company, has recently announced the randomization of the first patient in a registrational trial of its experimental gene therapy OTL-203 as a treatment for Mucopolysa...

Feb 5, 2024 • Biotechnology & Pharmaceuticals Industry Product Service News

Revolutionary Paradigms: HSC Gene Therapy and Newborn Screening in Severe Neurometabolic Diseases

The 20th Annual WORLDSymposium witnessed several enlightening presentations and posters by Orchard Therapeutics, showcasing groundbreaking advancements in hematopoietic stem cell (HSC) gene therapy and newborn screening...

Feb 2, 2024 • Biotechnology & Pharmaceuticals Industry Product Service News

“Global Gene Therapy Leader, Orchard Therapeutics, Expands Reach: Reimbursed Access to Libmeldy Granted in Beneluxa Member Countries

Orchard Therapeutics, a leading player in the global gene therapy industry, announced a crucial agreement with the Beneluxa Initiative on Pharmaceutical Policy, also known as Beneluxa, on January 25, 2024. With this agr...

Jan 25, 2024 • Biotechnology & Pharmaceuticals Industry Product Service News

Kyowa Kirin's Acquisition of Orchard Therapeutics: Pioneering Gene Therapies for Rare Diseases Opens New Avenues of Growth

Leading biotechnology company, Kyowa Kirin, has successfully completed its acquisition of Orchard Therapeutics, a global leader in gene therapy for rare diseases. This strategic move aligns with Kyowa Kirin s vision of...

Jan 24, 2024 • Biotechnology & Pharmaceuticals Industry Merger and Acquisition

Orchard Therapeutics Granted Fast Track Designation for OTL-203, Yet Slower Revenue Growth Poses Challenges in the Competitive Gene Therapy Market

In a promising development for the rare genetic disorder known as mucopolysaccharidosis type I-Hurler syndrome (MPS-IH), Orchard Therapeutics has been granted Fast Track Designation by the U.S. Food and Drug Administrat...

Nov 30, 2023 Clinical Study